CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Cychem

Cychem is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Corin Group

Exela Pharma Sciences

Exela Pharma Sciences is a Lenoir, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioheart

Founded in 1999, Bioheart, Inc. is committed to the development of effective cell technologies to treat cardiovascular diseases.

Sterling Pharma Solutions

Sterling is a CDMO or contract development and manufacturing organisation (/contract manufacturer organisation) with facilities in the UK and US.